Stocktwits Cycc (2024)

1. CYCC Cyclacel Pharmaceuticals Inc

Earnings
Track Cyclacel Pharmaceuticals Inc (CYCC) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateGlobe Newswire • 3 months ago ... (NASDAQ: CYCC, ...
Find Cyclacel Pharmaceuticals, Inc. (CYCCP) news, corporate events, press releases, latest company updates and headlines

View Cyclacel Pharmaceuticals, Inc. CYCC stock quote prices, financial information, real-time forecasts, and company news from CNN.

The current price of CYCC is 1.75 USD — it has increased by 6.06% in the past 24 hours. Watch Cyclacel Pharmaceuticals, Inc. stock price performance more ...
View live Cyclacel Pharmaceuticals, Inc. chart to track its stock's price action. Find market predictions, CYCC financials and market news.
See Also
Savings Card & Support | LOKELMA for Oral Suspension | For HCPs Drug Trials Snapshots: LOKELMA Pretendlunch Videos Canadian Laws Security Guards Need To Know About

Based on 1 Wall Street analysts offering 12 month price targets for Cyclacel Pharmaceuticals in the last 3 months. The average price target is $11.00 with a ...
Cyclacel Pharmaceuticals Stock forecast & analyst price target predictions based on 1 analysts offering 12-months price targets for CYCC in the last 3 months.

Cyclacel Pharmaceuticals (CYCC). (Delayed Data from NSDQ). $1.59 USD. 1.59. 57,661. -0.07 (-4.36%). Updated Jun 25, 2024 04:00 PM ET.
View Cyclacel Pharmaceuticals, Inc CYCC investment & stock information. Get the latest Cyclacel Pharmaceuticals, Inc CYCC detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.

Get Cyclacel Pharmaceuticals Inc (CYCC:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.

CYCC - Cyclacel Pharmaceuticals Inc - Stock screener for investors and traders, financial visualizations.
See Also
Gillette Fusion 5 vs ProGlide - Differences Compared Side-by-Side

Stock analysis for Cyclacel Pharmaceuticals Inc (CYCC:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company ...
To continue, please click the box below to let us know you're not a robot.

CYCC's current price target is $11.00. Learn why top analysts are making this stock forecast for Cyclacel Pharmaceuticals at MarketBeat.

Enduring — at least two decades of dividend payments. Start slideshow: Top 25 S.A.F.E. Dividend Stocks. CYCC split history picture. Cyclacel Pharmaceuticals ( ...
A CYCC split history review and split-adjusted CAGR.

CYCC has Very Good News after the market close --- no more share's dilution to raise the cash till 12/31/2022! CYCC has $4.76 per share Cash Value and $5.03 per ...
Find the latest Cyclacel Pharmaceutical Inc (CYCC) discussion and analysis from iHub's community of investors.

Cyclacel Pharmaceuticals, a biopharmaceutical company, closed an $8.0 million private placement under NASDAQ rules, offering shares of common stock, series A ...
Stay updated with the latest news and developments on Cyclacel Pharmaceuticals Inc (CYCC), a leader in targeted cancer therapies and innovative drug development.

Current Technical Analysis and interactive chart for $CYCC stock / shares. See the current trading strategy, trend(s), rating and buy and sell signals.

Cyclacel Pharmaceuticals (CYCC) has a Smart Score of N/A based on an analysis of 8 unique data sets, including Analyst Recommendations, Crowd Wisdom, ...
Cyclacel Pharmaceuticals (CYCC) has a Smart Score of N/A based on an analysis of 8 unique data sets, including Analyst Recommendations, Crowd Wisdom, and Hedge Fund Activity.

Jan 9, 2024 · Cyclacel Pharmaceuticals is no longer in danger of being delisted after managing to boost its share price above the $1 minimum bid requirement.
Cyclacel Pharmaceuticals stock is slipping on Tuesday after shares of CYCC rallied on Monday alongside it regaining Nasdaq compliance.